Contrasting Curaleaf (CURLF) & Its Peers

Curaleaf (OTCMKTS:CURLF) is one of 511 public companies in the “Healthcare Equipment & Supplies” industry, but how does it weigh in compared to its competitors? We will compare Curaleaf to related companies based on the strength of its earnings, risk, analyst recommendations, dividends, valuation, profitability and institutional ownership.

Volatility & Risk

Curaleaf has a beta of 1.55, suggesting that its stock price is 55% more volatile than the S&P 500. Comparatively, Curaleaf’s competitors have a beta of 2.55, suggesting that their average stock price is 155% more volatile than the S&P 500.

Profitability

This table compares Curaleaf and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Curaleaf	-2.62%	-0.88%	-0.26%
Curaleaf Competitors	-278.23%	-150.07%	-21.87%

Insider & Institutional Ownership

0.0% of Curaleaf shares are owned by institutional investors. Comparatively, 40.5% of shares of all “Healthcare Equipment & Supplies” companies are owned by institutional investors. 14.8% of shares of all “Healthcare Equipment & Supplies” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Curaleaf and its competitors gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Curaleaf	$1.27 billion	-$231.07 million	-63.62
Curaleaf Competitors	$1.87 billion	$138.21 million	10.70

Curaleaf’s competitors have higher revenue and earnings than Curaleaf. Curaleaf is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a breakdown of recent recommendations for Curaleaf and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Curaleaf	0	1	2	1	3.00
Curaleaf Competitors	4251	10479	18202	824	2.46

Curaleaf currently has a consensus price target of $6.00, indicating a potential downside of 27.45%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 25.65%. Given Curaleaf’s competitors higher probable upside, analysts clearly believe Curaleaf has less favorable growth aspects than its competitors.

Summary

Curaleaf competitors beat Curaleaf on 8 of the 13 factors compared.

Curaleaf Company Profile

Curaleaf Holdings, Inc. operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles. It also provides hemp-based products and cannabinoids, such as cannabidiol and cannabigerol. In addition, the company engages in the cultivation, production, and sale of cannabis products through retail and wholesale channels. The company is headquartered in New York, New York.